Cardiff Oncology Announced Initial Data From The CRDF-004 Phase 2 Trial Evaluating Onvansertib In Combination With Standard-of-care In Patients With First-Line RAS-Mutated Metastatic Colorectal Cancer
Cardiff Oncology Announced Initial Data From The CRDF-004 Phase 2 Trial Evaluating Onvansertib In Combination With Standard-of-care In Patients With First-Line RAS-Mutated Metastatic Colorectal Cancer
Cardiff Oncology宣布了初始数据，来自于CRDF-004第2期试验，评估Onvansertib与标准治疗结合在首线RAS突变转移性结直肠癌患者中的效果。
- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm.
- In the experimental arms, 30mg dose of onvansertib demonstrated a higher ORR compared to 20mg dose of onvansertib (64% vs. 50%) with deeper tumor regression in the 30mg arm.
- Onvansertib was well tolerated at both doses.
- Additional clinical data from CRDF-004 trial expected in 1H 2025.
- 对RAS突变的转移性结直肠癌进行的随机二期CRDF-004临床试验的初步结果显示，在30mg onvansertib剂量组中，ORR为64%，而对照组的ORR为33%。
- 在实验组中，3000万剂量的onvansertib显示出比20mg剂量的onvansertib更高的ORR（64% vs. 50%），且在30mg组中肿瘤回归更明显。
- onvansertib在两种剂量下均耐受良好。
- 预计在2025年上半年将推出CRDF-004试验的附加临床数据。
资讯热榜
更新时间